Mary Mirabelli Buys Shares of Genelux Corporation

Mary Mirabelli, an insider at Genelux Corporation, purchased 31,566 shares on June 16, 2026. Although the transaction price wasn't disclosed, this move reflects confidence in the company's prospects. Genelux trades on the NasdaqCM under the ticker GNLX.

Other Institutional Activity in Genelux Corporation

Several institutional investors have been active in Genelux Corporation recently. Woodward Diversified Capital, LLC increased its holdings by 184,472 shares, bringing its total to 2,117,183 shares valued at about $5.91 million. Vanguard Capital Management LLC added 1,695,480 shares, now holding the same number worth approximately $4.10 million. Bleichroeder LP significantly boosted its position by 666,666 shares, ending with 1,380,666 shares valued at $3.34 million. Meanwhile, Geode Capital Management, LLC grew its stake by 72,354 shares to 453,761 shares, valued at $1.10 million. BlackRock, Inc. also added 20,564 shares, holding 405,872 shares worth around $982,210.

Genelux Corporation Stock Snapshot

Shares of NasdaqCM:GNLX traded near $2.965. Genelux Corporation has a market cap of approximately $133 million. It has a forward P/E ratio of -3.89, indicating it isn't profitable, and a beta of 0.55, suggesting lower volatility compared to the market. The stock's 52-week range spans from $2.29 to $8.535, with a 50-day moving average of $2.8385 and a 200-day moving average of $3.727675. The company maintains a current ratio of 3.679 and a quick ratio of 3.604, with a debt-to-equity ratio of 10.885.

Recent Earnings

Genelux Corporation reported $8,000 in revenue, with no growth figures available. The company is not currently profitable, with an EPS of -0.85. Its return on equity stands at -127.28%, and it has a net margin of 0%. The next earnings report is anticipated on May 6, 2025.

Insider Buying and Selling at Genelux Corporation

On June 16, 2026, several insiders at Genelux Corporation, including Mary Mirabelli, John Smither, James Tyree, and Chief Scientific Officer Yong Yu, purchased shares. Mirabelli, Smither, Tyree, and John Thomas each acquired 31,566 shares, while Yu bought 119,318 shares. These transactions were not part of any pre-planned trading programs.

Analysts Set New Price Targets

On March 20, 2026, Benchmark maintained its buy rating on Genelux Corporation with a price target of $20. Other analysts have also shown optimism: Lake Street initiated coverage with a buy rating and a $16 target on October 21, 2025, while HC Wainwright & Co. reiterated their buy rating with a $30 target on March 25, 2025. Overall, the consensus among six analysts is a buy rating, with a mean price target of $17.50.

About Genelux Corporation

Genelux Corporation, headquartered in Westlake Village, California, is a clinical-stage biopharmaceutical company in the healthcare sector, specifically in biotechnology. It focuses on developing oncolytic viral immunotherapies for treating aggressive solid tumors. Its lead product, Olvi-Vec, targets ovarian cancer. The company also offers the CHOICE technology platform and has a significant library of immunotherapeutic product candidates. Genelux collaborates with Newsoara BioPharma Co. Ltd. for research and commercialization in China.

Bottom Line

Mary Mirabelli's recent share purchase in Genelux Corporation highlights insider interest in the company. Investors often watch insider transactions for potential insights into a company's future. However, it's important to remember that such transactions are backward-looking and may not reflect the company's current or future performance. As always, investors should consider a comprehensive set of factors when evaluating stock opportunities.